No TB drug lawsuits, J&J promises

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

No TB drug lawsuits, J&J promises

Markham, Ontario, Canada - May 21, 2018: Johnson & Johnson Medical Products company in Markham, Ontario, a division of  Johnson & Johnson Inc.

Johnson & Johnson won’t enforce patents for bedaquiline after months of public scrutiny and new licences for generics

Activists have hailed a “sea change” in the treatment of tuberculosis after Johnson & Johnson agreed not to enforce patents covering bedaquiline on Friday, September 29.

J&J said the decision was intended to reassure generics makers that they could market cheaper versions of bedaquiline, a TB drug, in 134 low- and middle-income countries.

In July, the company granted licences for the drug to the UN-backed Stop TB Partnership’s Global Drug Facility.

J&J has faced significant pressure from activists and civil society groups this year over its patent portfolio on bedaquiline.

Bestselling author John Green was among those to lend his voice to a campaign calling on J&J to halt its efforts to secure additional patents on bedaquiline, with the core intellectual property rights set to expire this year.

In March, India’s IP office refused J&J’s application for a secondary patent on bedaquiline after a challenge brought by two TB survivors.

Last month, meanwhile, South Africa’s Competition Commission launched an investigation after it emerged the country wouldn’t benefit from lower prices for the drug worldwide.

Prices for bedaquiline fell sharply after July’s deal with the Global Drug Facility.

J&J now charges most lower-income countries a headline price of $130 for a six-month course of the drug, but South Africa will continue to pay the old figure of $289.

A J&J spokesperson said the company would cooperate fully with the investigation.

Christophe Perrin, TB advocacy pharmacist at Médecins Sans Frontières’s Access Campaign, said the decision announced on Friday, September 29, was “testament to the persistent efforts of TB activists, civil society, and also countries prioritising public health over corporations' interests”.

Perrin called on Japanese drugmaker Otsuka, which owns patents for the drug delamanid, to match J&J’s pledge not to enforce its IP.

Delamanid is often used in combination with bedaquiline to treat multidrug-resistant TB.

“We need all newer TB innovations to be as affordable as absolutely possible, so governments can scale up prevention, testing and treatment to beat back this curable disease that continues to kill 1.6 million people every year.

“People with TB literally cannot afford to wait any longer,” Perrin said.

more from across site and SHARED ros bottom lb

More from across our site

Simon Tønners explains why IP provides the chance to work with some of the most passionate, risk-taking, and emotionally invested clients
The co-leaders of the firm’s new SEP practice group say the team will combine litigation and prosecution expertise to guide clients through cross-border challenges
Boasting four former Spruson & Ferguson leaders and with offices in Hong Kong and Singapore, the IP firm aims to provide fast, practical advice to clients
Partners at three law firms explain why trade secrets cases are rising, and how litigation is giving clients a market advantage
Delegates at a conference unpicking the UK’s relationship with the UPC are hopeful of strengthened UK involvement – so should we all be
News of a litigation funder suing its co-founder and a law firm over trade secrets infringement, and a strategic hire by Womble Bond Dickinson were also among the top talking points
Managing IP’s parent company, LBG, will acquire The Lawyer, a leading news, intelligence, and data-driven insight provider for the legal industry, from Centaur Media
In major recent developments, a team of partners broke away from Taylor Wessing to form their own firm, while Kilburn & Strode made a strategic UPC hire
General Court backs Christian Archambeau in some of his challenges against his departure, but dismisses others
Morgan Lewis adds three partners with technical depth, reinforcing the firm’s strategy to bridge legal and tech expertise in patent litigation
Gift this article